

Director of Laboratories: Dr L Gaunt

## **REQUEST FOR CNS TUMOUR DNA TESTING**

PLEASE COMPLETE SECTION 1-3 AND EITHER FORWARD TO THE PATHOLOGY LABORATORY HOLDING THE SAMPLE, OR IF YOU REQUIRE THE GENOMIC DIAGNOSTICS LABORATORY TO OBTAIN THE SPECIMEN PLEASE FORWARD TO mft.Pharmaco.GeneticsRequests@nhs.net. SECTION 4 IS INTENDED TO BE COMPLETED BY THE PATHOLOGY LABORATORY.		
<b>1. PATIENT DETAILS (affix a printed label if available)</b> Sex: M  F		
Forename(s):		
2. REFERRER DETAILS		
Consultant:		
Address for reporting/		
invoicing:		
Tel:		
Email <sup>1</sup>		
<sup>4</sup> Reports will be sent to multiple emails if required (requires account registration for secure email - contact laboratory for further information)		
3. TEST REQUEST (please select options by placing a tick or cross next to each test required)  Required    1. Please note that all genes are tested and reported and this test may identify pathogenic germline variants. 2. NGS panel testing also available for research or clinical trial support; 3. If a hypermethylation test in addition to another test is required please send a further 4 x 5uM sections; 4. For KIAA1549:BRAF fusion, C110r95:RELA fusion, and EGFRvIII transcript testing please send 4x 5µM rolls 5. See overleaf for sample requirements.    hTERT promoter mutations  MGMT <sup>3</sup> promoter hypermethylation    1p19q FISH <sup>5</sup> BRAF codon 600 mutation testing		
KIAA1549:BRAF fusion <sup>4</sup>		
C11orf95:RELA fusion <sup>4</sup>		
EGFRvIII transcript <sup>4</sup>		
Meningioma/schwannoma panel <sup>1</sup> (NF2, SMARCB1, SMARCE1, SMARCA4, LZTR1)		
NGS Glioma sub-panel <sup>22</sup> – please circle any genes where analysis is a priority (AKT1; ALK; BRAF; CTNNB1; ERBB2; FGFR3; H3F3A; IDH1; IDH2; KIT; KRAS; MAP2K1; MET; NRAS; PIK3CA; PTEN; TERT; TP53)		
NGS somatic cancer panel testing CTNNB1; DDR2; EGFR; ERBB2; FG PIK3CA; PTEN; RET; STK11; TP53,	<sup>42</sup> – please circle any genes where analysis is a priority (AKT1; ALK; AR; BRAF; FR3; GNA11; GNAQ; IDH1; IDH2; KIT; KRAS; MAP2K1; MET; NRAS; PDGFRA; H3F3A, TERT)	
4. PATHOLOGY AND CLINICAL DETAILS		
Tumour Type/origin of organ: Pathologist: Hospital/Trust: Pathology Block/Sample No: Date sections sent to Genetics la	b:	
Please indicate the approximate tumour cell content of the sample sent for analysis:    (this information is important and is used to ensure the test carried out is appropriately sensitive)    <10%*		
*If sample is suitable for macrodissection, please include an H&E stained section with area(s) of tumour clearly circled and an estimate of neoplastic cell content within marked area%		

## **INFORMATION FOR PATHOLOGY LAB (ALL SAMPLES)**

- We require a minimum of 4x5uM unstained slide mounted sections or rolls from a pathology block. This excludes KIAA1549:BRAF fusion, C110rf95:RELA fusion, and EGFRvIII transcript testing where we require a minimum of 4 x 5μM rolls or pathology blocks.
- We accept pathology blocks, but unstained slides are preferred (if pathology blocks are sent, TAT may increase by up to 7 calendar days for sample processing).
- If insufficient tissue available please contact the laboratory for advice.
- If neoplastic cell content is <30% and sample suitable for macrodissection please also send a H&E stained slide with the area of tumour ringed and an estimate of neoplastic cell content within the marked area.
- Sections should be cut under conditions that prevent cross contamination from other specimens.
- Slides carrying sections should be sent in a clean slide carrier. Slides must be clearly marked with a patient or sample identifier that matches details on this form or accompanying Pathology report. In addition please clearly label the container with at least 2 patient identifiers.
- Samples should be despatched as soon as possible as the patient's treatment is dependent on the results of Genomic analysis.
- Please send samples to the address at the letterhead above.

## FISH TEST

- Prepare 4 unstained sections (3uM thick) floated on the surface of a purified water bath set at 40°C (+/-2°C).
- Mount on positively charged slides and allowed to air-dry
- Also include 1 H&E slide with regions enriched for neoplastic cells marked by a Pathologist along with an estimate of neoplastic cell content in the marked area(s)



In case of queries contact Helene Schlecht (<u>Helene.Schlecht@mft.nhs.uk</u>), George Burghel (<u>George.burghel@mft.nhs.uk</u>) Tel: 0161 276 3265 or Andrew Wallace (<u>Andrew.wallace@mft.nhs.uk</u>) Tel: 0161 701 4919 Form version 03/18